[ CAS No. 380380-64-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

2D 3D

Structure of 380380-64-3 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 380380-64-3 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 380380-64-3 ]

SDS Specification

Alternatived Products of [ 380380-64-3 ]

Product Details of [ 380380-64-3 ]

CAS No. :	380380-64-3	MDL No. :	MFCD06796604
Formula :	C₇H₆BrN₅	Boiling Point :	-
Linear Structure Formula :	-	InChI Key :	JANKGNBDRWYWSN-UHFFFAOYSA-N
M.W :	240.06	Pubchem ID :	23438653
Synonyms :

Calculated chemistry of [ 380380-64-3 ] Expand+

Physicochemical Properties

Num. heavy atoms :	13
Num. arom. heavy atoms :	11
Fraction Csp3 :	0.14
Num. rotatable bonds :	1
Num. H-bond acceptors :	4.0
Num. H-bond donors :	0.0
Molar Refractivity :	50.01
TPSA :	56.49 ?2

Pharmacokinetics

GI absorption :	High
BBB permeant :	Yes
P-gp substrate :	No
CYP1A2 inhibitor :	Yes
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.74 cm/s

Lipophilicity

Log Po/w (iLOGP) :	1.96
Log Po/w (XLOGP3) :	1.44
Log Po/w (WLOGP) :	1.03
Log Po/w (MLOGP) :	0.5
Log Po/w (SILICOS-IT) :	1.15
Consensus Log Po/w :	1.22

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	0.0
Bioavailability Score :	0.55

Water Solubility

Log S (ESOL) :	-2.8
Solubility :	0.384 mg/ml ; 0.0016 mol/l
Class :	Soluble
Log S (Ali) :	-2.23
Solubility :	1.41 mg/ml ; 0.00586 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-3.06
Solubility :	0.211 mg/ml ; 0.000879 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	0.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	2.31

Safety of [ 380380-64-3 ]

Signal Word:	Danger	Class:	4.1
Precautionary Statements:	P240-P210-P241-P264-P280-P302+P352-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313	UN#:	1325
Hazard Statements:	H315-H319-H228	Packing Group:	Ⅲ
GHS Pictogram:

Application In Synthesis of [ 380380-64-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 380380-64-3 ]
Downstream synthetic route of [ 380380-64-3 ]

[ 380380-64-3 ] Synthesis Path-Upstream 1~3

1
[ 380380-64-3 ]
[ 856866-72-3 ]

Yield	Reaction Conditions	Operation in experiment
48%	With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; lithium chloride In N,N-dimethyl-formamide at 90℃; for 4 h;	In a 100 ml reaction flask,Compound 7 (5.0 g, 10 mmol) and 50 ml of DMF were added,2- (1-methyl-tetrazol-5-yl) -5-bromopyridine (2.65, 11 mmol)Lithium chloride (1.7 g),1,1'-bis (diphenylphosphino) ferrocene] palladium chloride (1.0 g),The mixture was stirred at 90 ° C for 4 hours,After completion of the reaction,To room temperature,And extracted three times with water / ethyl acetate (V / V = 1: 1)The organic layers were combined,Dried over anhydrous sodium sulfate,And concentrated to give 1.7 g of the compound (1)The yield was 48percent
26%	With lithium chloride In 1-methyl-pyrrolidin-2-one at 20 - 120℃; for 4 h;	In 150ml of 1-methyl-2-pyrrolidone was dissolved 37g of (R)-3- (4- tributhylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol. The solution was added with 19.7g of 2- (2-methyltetrazol-5-yl)-5-bromopyridine, 10.44g of lithium chloride and 2.9g of dichlorobistriphenylphospine palladium (I I) at room temperature and then stirred at the temperature of 120 C for 4 hours. The reaction mixture was added with water and then extracted with ethyl acetate. The organic layer, thus separated, was washed with brine, dehydrated, filtrated, concentrated in vacuo and purified by column chromatography to provide 8g of the title compound. Yield 26percent. 1H NMR (DMSO-d6) 5 8.90 (s, lH), 8. 18 (m, 2H), 7.70 (m, 2H), 7.49 (dd, 1H), 5.25 (t, 1H), 4.74 (m, 1H), 4.46 (s, 3H), 4.14 (t, lH), 3. 88 (dd, lH), 3.68 (m, lH), 3. 58 (m, lH)
26%	With bis-triphenylphosphine-palladium(II) chloride; lithium chloride In 1-methyl-pyrrolidin-2-one at 120℃; for 4 h; Inert atmosphere	To a solution of (R)-3-(4-tributhylstannyl-3-fluorophenyl)-2-oxo-5-oxazolidinylmethanol 5 (37.0 g, 74.0 mmol) in NMP (150 mL) was added 2-(2-methyltetrazol-5-yl)-5-bromopyridine 9 (19.7 g, 81.9 mmol), LiCl (10.4 g, 245 mmol) and Pd(PPh₃)₂Cl₂ (2.90 g, 4.13 mmol). The reaction mixture was stirred for 4 h at 120 °C. After being cooled to room temperature, the reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous MgSO₄, filtered and concentrated in vacuo. The residue was further purified by column chromatography to obtain the title compound (8 g, 26percent). Mp: 201 °C. ¹H NMR (DMSO-d₆): δ 8.90 (s, 1H), 8.18 (m, 2H), 7.70 (m, 2H), 7.49 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 5.25 (t, J = 5.6 Hz, 1H), 4.74 (m, 1H), 4.46 (s, 3H), 4.14 (t, J = 8.8 Hz, 1H), 3.88 (m, 1H), 3.68 (m, 1H), 3.58 (m, 1H). ¹³C NMR (DMSO-d₆): δ 163.56, 159.03, 154.06, 149.18, 144.78, 140.30, 136.96, 131.42, 130.73, 121.89, 118.36, 113.81, 105.18, 73.39, 61.52, 45.96, 39.63. IR (neat, cm^-1): 3251.40, 1746.23, 1619.91, 1473.35, 1406.82. [M + H]⁺: 371.02. HRMS [EI-MS]: m/z, calculated for [C₁₇H₁₅FN₆O₃] 370.1190, found, 370.1100 [C₁₇H₁₅FN₆O₃].

Reference： [1] Patent: CN105859780, 2016, A, . Location in patent: Paragraph 0038
[2] Patent: WO2005/58886, 2005, A1, . Location in patent: Page/Page column 28; 29
[3] European Journal of Medicinal Chemistry, 2011, vol. 46, # 4, p. 1027 - 1039
[4] Patent: CN107400126, 2017, A, . Location in patent: Paragraph 0036

2
[ 444335-16-4 ]
[ 380380-64-3 ]
[ 856866-72-3 ]

Yield	Reaction Conditions	Operation in experiment
83%	Stage #1: With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)CH₂Cl₂; potassium acetate; bis(pinacol)diborane In dimethyl sulfoxide at 80℃; for 14 h; Inert atmosphere Stage #2: With dichloro(1,1'-bis(diphenylphosphanyl)ferrocene)palladium(II)CH₂Cl₂; caesium carbonate In 1,4-dioxane; water at 70℃; for 3 h; Inert atmosphere	DMSO (100 ml) was added to a 250 ml reaction flask,(5R) -3- (4-bromo-3-fluorophenyl) -5-hydroxymethyloxazolidin-2-one(10 g, 34.5 mmol), pinacolate (17.52 g, 69 mmol),[1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium dichloromethane complex (1.41 g, 1.73 mmol)And potassium acetate (13.5 g, 138 mmol), and the temperature was raised to 80 ° C under a nitrogen atmosphere,For 14 hours. The heating was stopped, the solution was cooled to room temperature, and extracted with water / ethyl acetate 3 times. The organic layers were combined and the organic layer was washed with saturated waterBrine, dried over anhydrous sodium sulfate and concentrated by suction filtration. The concentrated product of the above step was added to a 250 ml reaction flask,1,4-dioxane (100 ml) was added,5-bromo-2- (2-methyl-2H-tetrazol-5-yl) pyridine(8.28 g, 34.5 mmol),[1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium dichloromethane complex (0.56 g, 0.69 mmol)And cesium carbonate aqueous solution (50 ml, containing 33.72 g of cesium carbonate, 103.5 mmol),Under nitrogen protection,The temperature was raised to 70 ° C,The reaction was carried out for 3 hours,Dichloromethane was added for extraction.The separated organic phase was washed with saturated brine,Anhydrous sodium sulfate dehydration,filter,Concentrated in vacuo and purified by column chromatography,10.6 g of a solid was obtained,The yield was 83.0percentHPLC purity was 98.34percent (area normalization method).

Reference： [1] Patent: CN105418678, 2016, A, . Location in patent: Paragraph 0070; 0071; 0072; 0073; 0074; 0075

3
[ 380380-64-3 ]
[ 856866-72-3 ]

Reference： [1] Chemical and Pharmaceutical Bulletin, 2015, vol. 63, # 2, p. 143 - 146

[ 380380-64-3 ] Synthesis Path-Downstream 1~4

1
[ 380380-60-9 ]
[ 74-88-4 ]
[ 380380-64-3 ]
[ 380380-63-2 ]

Yield	Reaction Conditions	Operation in experiment
	With sodium hydroxide; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 2h;	5-Bromo-2-(2-methyl-2H-tetrazol-5-yl) pyridine and 5-bromo-2- (1-methyl-1H-tetrazol-5- yl) pyridine. 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine and 5-bromo-2-(1-methyl-1H-tetrazol-5- yl) pyridine were prepared according to the procedure described by Dong A Pharmaceuticals (WO 01/94342). A mixture of 6.5 g unpurified 5-bromo-2-tetrazol-5-ylpyridine [Dong A Pharmaceuticals (WO 01/94342) ] (~28 mmol) and sodium hydroxide (9 g, 125 mmol) in dry dmf was evaporated to dryness under reduced pressure. A stirred solution of the involatile residue in dry DMF (50 mL) was treated dropwise at ice-bath temperature with iodomethane (3.0 ML, 48 mmol). The stirred reaction mixture was allowed to warm and then maintained at room temperature for 2 hours. The reaction mixture was partitioned between iced water and ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, and tehn evaporated under reduced pressure to give a residue that was purified by chromatography on silica gel [elution with dichloromethane : ethyl acetate (60: 1) ] to give: 1. 5-bromo-2- (1-methyl-1H-tetrazol-5-yl)pyridine (1.397 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 3), 1H-NMR (DMSO-d6) (300 MHz) 8 : 4.38 (s, 3H); 8.17 (d, 1H); 8.35 (dd, 1H); 8.96 (d, 1H). 2. 5-bromo-2-(2-methyl-2H-tetrazol-5-yl)pyridine (1.07 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf : 0. 1). 1H-NMR (DMSO-d6) (300 MHz) No. : 4.46 (s, 3H); 8.09 (d, 1H) ; 8.28 (dd, 1H) ; 8.88 (d, 1H).
	With sodium hydroxide; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 2h;	5-BROMO-2- (2-METHYL-2H-TETRAZOL-5-YL) PYRIDINE AND 5-BROMO-2- (L-METHYL-LH-TETRAZOL-5- YL) pyridine 5-Bromo-2-(2-methyl-2H-tetrazol-5-yl) pyridine and 5-BROMO-2- (1-METHYL-LH-TETRAZOL-5- YL) pyridine were prepared according to the procedure described by Dong A Pharmaceuticals (WO 01/94342). A mixture of 6.5 g unpurified <strong>[380380-60-9]5-BROMO-2-TETRAZOL-5-YLPYRIDINE</strong> [Dong A Pharmaceuticals (WO 01/94342)] (-28 mmol) and sodium hydroxide (9 g, 125 mmol) in dry DMF was evaporated to dryness under reduced pressure. A stirred solution of the involatile residue in dry DMF (50 ML) was treated dropwise at ice-bath temperature with iodomethane (3.0 mL, 48 mmol). The stirred reaction mixture was allowed to warm and then maintained at room temperature for 2 hours. The reaction mixture was partitioned between iced water and ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, and tehn evaporated under reduced pressure to give a residue that was purified by chromatography on silica gel [elution with dichloromethane : ethyl acetate (60: 1) ] to give: 1. 5-bromo-2-(1-methyl-1H-tetrazol-5-yl) pyridine (1.397 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0.3),'H-NMR (DMSO-D) (300 MHz) 8 : 4.38 (s, 3H); 8.17 (d, 1H); 8.35 (dd, 1H); 8.96 (d, 1H). 2. 5-bromo-2-(2-methyl-2H-tetrazol-5-yl) pyridine (1.07 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 1). LH-NMR (DMSO-DSLT300 MHz) 8 4.46 (s, 3H); 8.09 (d, 1H); 8.28 (dd, 1H) ; 8.88 (d, 1H). Structure assignment based on nmr HMBC experiments, in which long range coupling of the protons of CH3 to the C5 of the tetrazole ring is observed in the 1-methyl-1H-isomer of Rf 0.3, but not in the 2-methyl-2H-isomer of Rf 0.1). The compound referred to as 5-bromo-2- (1-METHYL-LH-TETRAZOL-5-YL) pyridine is thus the isomer of Rf 0.3 and the compound referred to as 5-BROMO-2-(2-METHYL-2H-TETRAZOL-5-YL) PYRIDINE is thus the ISOMER OF RF 0. 1
	With sodium hydroxide; In DMF (N,N-dimethyl-formamide); at 0 - 20℃; for 2h;	5-BROMO-2-(2-METHYL-2H-TETRAZOL-5-YL) PENDINE AND 5-BROMO-2-(1-METHEL-LH-TETRAZOL-5- 1 pyridine 5-BROMO-2- (2-METHYL-2H-TETRAZOL-5-YL) PYRIDINE AND 5-BROMO-2- (L-METHYL-LH-TETRAZOL-5- yl) pyridine were prepared according to the procedure described by Dong A Pharmaceuticals (WO 01/94342). A mixture of 6.5 g unpurified <strong>[380380-60-9]5-BROMO-2-TETRAZOL-5-YLPYRIDINE</strong> [Dong A Pharmaceuticals (WO 01/94342)] (-28 mmol) and sodium hydroxide (9 g, 125 mmol) in dry DMF was evaporated to dryness under reduced pressure. A stirred solution of the involatile residue in dry DMF (50 ML) was treated dropwise at ice-bath temperature with iodomethane (3.0 mL, 48 mmol). The stirred reaction mixture was allowed to warm and then maintained at room temperature for 2 hours. The reaction mixture was partitioned between iced water and ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, and tehn evaporated under reduced pressure to give a residue that was purified by chromatography on silica gel [ELUTION WITH DICHLOROMETHANE: ETHYL ACETATE (60: 1) ] TO GIVE: 1. 5-BROMO-2-(1-METHYL-LH-TETRAZOL-5-YL) pyridine (1.397 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 3), 1H-NMR (DMSO-D6) (300 MHZ) 8 : 4.38 (s, 3H); 8.17 (d, 1H); 8.35 (dd, 1H); 8.96 (d, 1H). 2. 5-BROMO-2- (2-METHYL-2H-TETRAZOL-5-YL) pyridine (1.07 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 1). LH-NMR (DMSO-D) (300 MHZ) 8 4.46 (s, 3H); 8.09 (d, 1H) ; 8.28 (dd, 1H); 8.88 (d, 1H). Structure assignment based on HMBC experiments, in which long range coupling of the protons of CH3 to the C5 of the tetrazole ring is observed in the 1-METHYL-LH-ISOMER of Rf 0.3, but not in the 2-methyl-2H-isomer of Rf 0.1). The compound referred to as 5-bromo-2- (1-METHYL-1H-TETRAZOL-5-YL) PYRIDINE is thus the isomer of Rf 0.3 and the compound referred to as 5-BROMO-2-(2-METHYL-2H-TETRAZOL-5-YL) PYRIDINE is thus the isomer OF RF 0. 1

		A mixture of 6.5 g unpurified 5-bromo-2-tetrazol-5-ylpyridine [Dong A Pharmaceuticals (WO 01/94342)] (-28 mmol) and sodium hydroxide (9 g, 125 mmol) in dry DMF was evaporated to dryness under reduced pressure. A stirred solution of the involatile residue in dry DMF (50 ML) was treated dropwise at ice-bath temperature with iodomethane (3.0 mL, 48 mmol). The stirred reaction mixture was allowed to warm and then maintained at room temperature for 2 hours. The reaction mixture was partitioned between iced water and ethyl acetate. The organic phase was washed with water, dried over magnesium sulfate, and tehn evaporated under reduced pressure to give a residue that was purified by chromatography on silica gel [elution with dichloromethane: ethyl acetate (60: 1) ] to give: 1. 5-BROMO-2- (L-METHYL-LH-TETRAZOL-5-YL) pyridine (1.397 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 3), (DMSO-D6) (300 MHZ) 8 : 4.38 (s, 3H); 8.17 (d, 1H) ; 8.35 (dd, 1H); 8.96 (d, 1H). 2. 5-BROMO-2- (2-METHYL-2H-TETRAZOL-5-YL) pyridine (1.07 g), a colorless solid, (TLC: silica-gel, hexanes: ethyl acetate (4: 1), Rf: 0. 1). 1H-NMR (DMSO-D6) (300 MHZ) 8 4.46 (s, 3H); 8.09 (d, 1H); 8.28 (dd, 1H); 8.88 (d, 1H). Structure assignment based on HMBC experiments, in which long range coupling of the protons of CH3 to the C5 of the tetrazole ring is observed in the 1-METHYL-LH-ISOMER of Rf 0.3, but not in the 2-methyl-2H-isomer of Rf 0.1). The compound referred to as 5-bromo-2- (1-METHYL-LH-TETRAZOL-5-YL) pyridine is thus the isomer of Rf 0.3 and the compound referred to as 5-BROMO-2- (2-METHYL-2H-TETRAZOL-5-YL) pyridine is thus the isomer OF RF 0. 1
	With potassium hydroxide; In N,N-dimethyl-formamide; at 20℃; for 23h;	To the solution of crude <strong>[380380-60-9]5-bromo-2-(2H-tetrazol-5-yl)pyridine</strong>(3.15 g,.13.9 mmol) in DMF (32 mL) was added MeI (7.92 g, 55.8 mmol) and KOH (1.95 g, 34.8 mmol) at room temperature. The mixture was stirred for 23 h at r.t.. The reaction mixture was poured into ice water (100 mL) and extracted with EtOAc. The organic layer was washed with brine, dried (Na2SO4), and evaporated under vacuum to give a residue, further purified by flash column chromatography (hexanes - EtOAc from 50: 1 to 10:1) to give 5-bromo-2- (2-methyl-2H-tetrazol-5-yl)pyridine as yellow solid (1.32 g, 43% yield over 2 steps) and 5- bromo-2-(l-methyl-lH-tetrazol-5-yl)pyridine as a white solid (0.97 g, 32% yield, 2 steps).

Reference： [1]European Journal of Organic Chemistry,2016,vol. 2016,p. 1305 - 1313
[2]Patent: WO2004/48350,2004,A2 .Location in patent: Page 60-61
[3]Patent: WO2004/56819,2004,A1 .Location in patent: Page 52-53
[4]Patent: WO2004/56818,2004,A1 .Location in patent: Page 52-53
[5]Patent: WO2004/56816,2004,A1 .Location in patent: Page 52-53
[6]Patent: WO2008/108988,2008,A1 .Location in patent: Page/Page column 52

2
[ 380380-60-9 ]
[ 50-00-0 ]
[ 380380-64-3 ]

Yield	Reaction Conditions	Operation in experiment
90.4%	With palladium 10% on activated carbon; hydrogen; In methanol; at 20℃; under 1500.15 Torr; for 3h;	1.5 L of methanol,5-bromo-2- (2H-tetrazol-5-yl) pyridine (226 g)Formaldehyde (90g),10% palladium on carbon (20 g) was added to the reactor,Under a hydrogen atmosphere (0.2 MPa)Stirred at room temperature for 3 hours, the reaction was completed,Organic phase evaporated,Recrystallization from acetonitrile,To give the product 2-methyl-5- (5-bromo-2-yl) tetrazolium,217 g, yield: 90.4%.

Reference： [1]Patent: CN106632240,2017,A .Location in patent: Paragraph 0018-0019

3
[ 380380-60-9 ]
[ 74-88-4 ]
[ 380380-64-3 ]

Yield	Reaction Conditions	Operation in experiment
70.5%	With calcium hydroxide; In dichloromethane; N,N-dimethyl-formamide; at 0 - 40℃; for 24h;	The <strong>[380380-60-9]5-bromo-2-(2H-tetrazol-5-yl)pyridine</strong> (20.0 g, 88.4 mmol) prepared in Example 1 was added with 20.0 mL of N,N-dimethyl formamide and 180.0 mL of methylene chloride and then further added with calcium hydroxide (3.94 g, 53.0 mmol), after which iodomethane (33.0 mL, 530.4 mmol) was slowly added dropwise thereto at 0C. Thereafter, the reaction solution was warmed to 40C and stuffed for 24 hr. After the termination of the reaction, the reaction solution was added with water, thus extracting an organic layer. The extracted organic layer was washed with saline and further extracted. The resulting organic layer was added with 300.0 mL of a 6 N hydrochloric acid aqueous solution to thus extract an aqueous layer, after which the separated organic layer was added with 60.0 mL of a 6 N hydrochloric acid aqueous solution, so that the aqueous layer was further extracted. Extraction was performed using HPLC until the amount of Ni was less than 5%. The separated aqueous layer was collected, and the pH thereof was adjusted to 10.6 at 40C or less using a 50% sodium hydroxide aqueous solution. The produced solid was filtered, washed with water, and concentrated under reduced pressure, thus obtaining a desired compound. Yield (16.2 g, 70.5%), N2/N] ratio % (98/2)

Reference： [1]Patent: WO2017/99530,2017,A1 .Location in patent: Paragraph 51; 52; 53; 54; 55; 56; 57

4
[ 380380-60-9 ]
[ 18107-18-1 ]
[ 380380-64-3 ]

Yield	Reaction Conditions	Operation in experiment
28.5%	In tetrahydrofuran; hexane; at 0 - 20℃; for 3h;	To a stirred mixture of 5-bromo-2-(2//-tctrazol-5-yl)pyridinc (452 mg, 2 mmol) in THF (5 mL) was added (diazomethyl)trimethylsilane in hexane (2M, 5 mL, 10 mmol) at 0 C. The reaction mixture was stirred at room temperature for 3 h. TLC showed the reaction completed. The reaction mixture was quenched with water (30 mL) and extracted with ethyl acetate (10 mL><3). The combined organic layers were washed with water and brine, dried over sodium sulfate and concentrated in vacuo. The crude product was purified by column chromatography to afford the title compound as white solid (l80mg,28.5 % yield). NMR (500 MHz, DMSO-r/d) S: 9.00 - 8.89 (m, 1H), 8.32 (dd, J= 8.5, 2.4 Hz, 1H), 8.14 (d, J= 8.4 Hz, 1H), 4.34 (s, 3H).

Reference： [1]Patent: WO2020/2968,2020,A1 .Location in patent: Page/Page column 45-46

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

? Alkyl Halide Occurrence ? General Reactivity ? Grignard Reaction ? Hiyama Cross-Coupling Reaction ? Kinetics of Alkyl Halides ? Kumada Cross-Coupling Reaction ? Preparation of Amines ? Reactions of Alkyl Halides with Reducing Metals ? Reactions of Amines ? Reactions of Dihalides ? Stille Coupling ? Substitution and Elimination Reactions of Alkyl Halides ? Suzuki Coupling

Historical Records

Related Functional Groups of
[ 380380-64-3 ]

Bromides

[ 1211516-09-4 ]

6-Bromo-1H-pyrazolo[4,3-b]pyridin-3-amine

Similarity: 0.66

[ 1150617-54-1 ]

6-Bromo-1H-pyrazolo[4,3-b]pyridine

Similarity: 0.60

[ 1150617-56-3 ]

6-Bromo-1-methyl-1H-pyrazolo[4,3-b]pyridine

Similarity: 0.56

[ 1251953-03-3 ]

(5-Bromopyridin-2-yl)methanamine dihydrochloride

Similarity: 0.56

[ 173999-23-0 ]

(5-Bromopyridin-2-yl)methanamine

Similarity: 0.55

Related Parent Nucleus of
[ 380380-64-3 ]

Pyridines

[ 1056039-83-8 ]

2-(2-Methyl-2H-tetrazol-5-yl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

Similarity: 0.65

[ 3250-74-6 ]

3-(2H-Tetrazol-5-yl)pyridine

Similarity: 0.57

[ 1251953-03-3 ]

(5-Bromopyridin-2-yl)methanamine dihydrochloride

Similarity: 0.56

[ 51285-26-8 ]

Picolinimidamide hydrochloride

Similarity: 0.55

[ 173999-23-0 ]

(5-Bromopyridin-2-yl)methanamine

Similarity: 0.55

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

[ CAS No. 380380-64-3 ] {[proInfo.proName]}

Quality Control of [ 380380-64-3 ]

Related Doc. of [ 380380-64-3 ]

Product Details of [ 380380-64-3 ]

Calculated chemistry of [ 380380-64-3 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 380380-64-3 ]

Application In Synthesis of [ 380380-64-3 ]

[ 380380-64-3 ] Synthesis Path-Upstream 1~3

[ 380380-64-3 ] Synthesis Path-Downstream 1~4

Technical Information

Related Functional Groups of [ 380380-64-3 ]

Bromides

Related Parent Nucleus of [ 380380-64-3 ]

Pyridines

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Related Functional Groups of
[ 380380-64-3 ]

Related Parent Nucleus of
[ 380380-64-3 ]